Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,861 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05057845RecruitingPhase 2
Freezing treatment plus immunotherapy and a pill for liver cancer
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04991948RecruitingPhase 1
Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Jacksonville, FloridaAges 18 years+ - NCT06513624RecruitingPhase 1
ETC-159 plus pembrolizumab for advanced ovarian cancer
This trial tests a new combination of two drugs—ETC-159 (a pill that targets a specific growth pathway) and pembrolizumab (an immunotherapy)—for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Singapore, SingaporeAges 21–99 - NCT05276310RecruitingPhase 1
Test IMC-002 for advanced solid tumors after standard treatment fails
This Phase 1 study tests IMC-002 in people with advanced cancers that did not respond to standard therapy. It may help by trying a new immune-targeting drug approach when other options have failed.
Goyang-siAges 19 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT05085496RecruitingPhase 1
Radiation plus atezolizumab for advanced skin cancer
This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.
Duarte, CaliforniaAges 18 years+ - NCT04423185RecruitingPhase 2
Precision medicine trial for rare advanced solid tumors
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
BeijingAges 18 years+ - NCT04144569RecruitingPhase 2
PD-1 plus pyrotinib for HER2-mutated lung cancer after chemo
This trial tests a combination treatment—PD-1 plus pyrotinib—in people with advanced lung cancer that has a specific HER2 “insertion” genetic change. It may help if your first standard chemotherapy did not work and you still have measurable tumors to track.
Changsha, HunanAges 18–75 - NCT05412082RecruitingPhase 1
Smart chemo and radiation plan for locally advanced rectal cancer
This Phase 1 study tests a “smart” total treatment plan using chemotherapy (chemo) and radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach is safe and can work well while helping plan treatment based on your situation.
Miami, FloridaAges 18 years+ - NCT05504278RecruitingPhase 1
Testing IBI351 with chemotherapy for KRAS G12C lung cancer
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
Jilin City, ChangchunAges 18–75 - NCT03375983RecruitingPhase 1/Phase 2
Immune treatment with malaria cells for advanced solid cancers
This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT05019690RecruitingPhase 1/Phase 2
Test drug combo for advanced triple-negative breast cancer
This trial studies how well apatinib plus albumin-bound paclitaxel works for advanced triple-negative breast cancer that has come back or spread. It may help shrink tumors and control the disease by targeting cancer growth in more than one way.
Fuzhou, FujianAges 18–75 - NCT04276857Recruiting
Chemo plus a local treatment for locally advanced pancreatic cancer
This study looks at how well combining standard chemo with a targeted local treatment works for people with locally advanced pancreatic cancer. It may help control the cancer in the area of origin and improve outcomes compared with chemo alone.
Regina, SaskatchewanAges Any age - NCT04192253RecruitingPhase 2
Carboplatin and paclitaxel before surgery for vulvar cancer
This trial tests giving chemotherapy (carboplatin and paclitaxel) before surgery for certain cases of squamous cell vulvar cancer. It may help shrink the tumor and make surgery more effective.
AmsterdamAges 18 years+ - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+ - NCT05605574Recruiting
Advance care planning talks for young transplant patients
This study tests a structured set of conversations about future medical care (advance care planning) for adolescents and young adults who are preparing for a stem cell transplant. It also involves a caregiver (and the care team) to help ensure the discussions are understood, documented, and completed at the right times.
Baltimore, MarylandAges 18–120 - NCT03474822RecruitingPhase 1/Phase 2
Plasmodium immune treatment for breast and liver cancers
This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT05341492RecruitingEarly Phase 1
CAR-T therapy for EGFR/B7H3-positive lung and triple-negative breast cancer
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07659158Recruiting
Virtual resilience program for advanced cancer patients
This trial tests a virtual group program to help people with advanced cancer build resilience and manage stress. It involves online sessions and modules, and aims to improve coping and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT06188624RecruitingPhase 1
Study of TQB2922 for advanced cancers
This trial tests a new drug, TQB2922, for people with advanced cancers that have not responded to standard treatments. The goal is to see if it is safe and how it affects the cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06157827RecruitingPhase 1/Phase 2
Testing LBL-024 plus chemo for advanced neuroendocrine carcinoma
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
Hefei, AnhuiAges 18–75 - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Daphne, AlabamaAges 18 years+ - NCT06038058RecruitingPhase 1
BRY812 for advanced solid tumors that have failed standard therapy
This trial tests an experimental drug called BRY812 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective against a protein called LIV-1 found on some cancer cells.
Guangzhou, GuangdongAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,861 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.